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In the past ten years, the concept of injecting stem and progenitor cells to assist with rebuilding damaged blood
vessels and myocardial tissue after injury in the heart and peripheral vasculature has moved from bench to bedside.
Non-invasive imaging can not only provide a means to assess cardiac repair and, thereby, cellular therapy efficacy
but also a means to confirm cell delivery and engraftment after administration. In this first of a two-part review, we
will review the different types of cellular labeling techniques and the application of these techniques in cardiovascular
magnetic resonance and ultrasound. In addition, we provide a synopsis of the cardiac cellular clinical trials that have
been performed to-date.
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In 2008, an estimated 17.3 million deaths were attributable
worldwide to cardiovascular diseasesa making cardiovas-
cular disease the leading cause of death worldwide. Cor-
onary heart disease (CHD) or diseases of the blood vessels
supplying the heart represents approximately 42% of these
deaths.a Because the heart lacks any significant regenera-
tive capacity, patients who do not die acutely after myo-
cardial infarction (MI) are at risk for development of heart
failure (HF) and sudden cardiac death related to ventricu-
lar arrhythmias. Among other factors, the extent of myo-
cardial damage is largely predictive of the likelihood of
future cardiac dysfunction and HF. Stem cell therapy
holds the promise of salvaging or reconstituting the elec-
tromechanical function of damaged heart tissue; thereby
preventing, mitigating, or possibly reversing CHD-related
heart failure and ventricular arrhythmia. Moreover, there
are a wide range of additional possible therapeutic uses of
stem cell to treat cardiovascular diseases (Figure 1).
Stem cells have two main characteristics: 1) the ability to
undergo clonal replication and 2) the capacity to differenti-
ate into multiple cell types. Pluripotent stem cells can* Correspondence: dkraitc1@jhmi.edu
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reproduction in any medium, provided the orbecome any cell type in the body with embryonic stem cells
as a classic example. Further, adult somatic cells have re-
cently been re-programmed to take on the characteristics
of embryonic stem cells —the so-called induced pluripo-
tent stem cells (iPS). Adult stem cells (or stem cells de-
rived from adult or non-embryonic/fetal tissue) are
generally considered to be multipotent, as opposed to
pluripotent, because of their inability to differentiate into
all lineages of cells. Due to the ease at which adult stem
and progenitor cells can be obtained and the lack of eth-
ical issues, these stem cells have been the most extensively
studied for cardiovascular applications. Examples of adult
stem cells include bone marrow- and adipose-derived mes-
enchymal stem cells (MSC), bone marrow mononuclear
stem cells, endothelial progenitor cells (EPC), and cardiac-
derived stem cells/cardiospheres (CSCs) [1,2].
Numerous patient studies using stem cell therapy for
CHD have already been performed (Table 1). Frequently,
major adverse cardiac events (MACE) are used as an
end point, such as repeat myocardial infarction or vascu-
lar procedures or death. Alternatively, imaging as a sur-
rogate endpoint for MACE can provide accurate and
reproducible measures of cardiac structure and function
[3]. Furthermore, imaging can provide a quantitative
measure for characterizing and comparing the efficacy of
stem cell therapies in the treatment of acute myocardial
infarction and heart failure. In turn, imaging may providetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Stem cell therapies can be envisioned to treat a wide variety of cardiovascular diseases ranging from preventing adverse
remodeling in ischemic and non-ischemic heart disease, the creation of new pacemaker cells, replacement of beta cells in Diabetes
Mellitus, and mitigating atherosclerotic disease leading to peripheral vascular disease as well as stroke.
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MACE endpoints cannot. With imaging as a primary out-
come, mixed results have been reported for clinical trials
of stem cell therapy in cardiovascular disease [4-11]. One
study reported greater improved left ventricular (LV) ejec-
tion fraction in the stem cell treatment group versus con-
trols (TOPCARE-AMI) [4,5]. A second study found initial
improvements but no sustained difference in LV ejection
fraction, LV end-diastolic volume, and LV end-systolic vol-
ume between groups (BOOST) [7]. A third study reported
no improvement in LVEF in the control group compared
to the stem cell group (ASTAMI) [8]. Whereas, a fourth
study using transendocardial administration of stem cells
resulted in significant positive remodeling of the peri-
infarction region (PROTECT-CAD) (Figure 2) [10,11]. A
fifth representative study using cardiac-derived stem cells
showed greater increases in left ventricular mass and larger
decreases in infarcted myocardium in the cell-treated pa-
tients [9]. The combination of these clinical studies, espe-
cially those with imaging data, and meta-analyses of these
trials, [12-16] suggests that stem cell administration is safe,
can provide improvements in cardiac function when stem
cells are administered at the appropriate time, improve-
ments in cardiac function appear to be related more to
paracrine than direct cell incorporation, some routes of ad-
ministration may provide more favorable results, and tim-
ing of cell delivery may be critical depending on the type
of cardiovascular disease.
Aside from assessing stem cell efficacy, imaging could
be an invaluable tool for monitoring delivery and/or
tracking stem cells fate by offering real-time guidance of
stem cell transplantation, cell transit, and engraftment.
In addition, the results of clinical trials could be tested
in relevant preclinical models to understand the mecha-
nisms underlying enhanced benefit from delivering stemcells at a certain time point, via certain routes, with certain
cell types or in certain disease entities. The efficacy of stem
cell therapy has been explored using all standard clinical
imaging modalities, i.e., cardiovascular magnetic resonance
(CMR), ultrasound (US), X-ray/computed tomography
(CT), positron emission tomography (PET), and single-
photon emission computed tomography (SPECT), along
with optical imaging modalities (OI), such as biolumines-
cence and fluorescence, in animal CHD models. To date,
no consensus, however, has been reached on the best
imaging modality to determine stem cell therapy effi-
cacy. Indeed, the “best” imaging modality may be highly
dependent on the availability of imaging equipment, the
suitability depending on the patient population, e.g.,
pediatrics vs. implanted devices, or the method of delivery,
e.g., intra-operatively vs. percutaneous.
For the purpose of stem cell tracking, the choice of
imaging system is integral to a cell labeling strategy; each
possessing advantages and disadvantages for cardiovas-
cular imaging, in general, and stem cell tracking, in par-
ticular (Table 2). The ideal imaging system is one that
does not produce ionizing radiation but has high spatial
resolution (ideally single cells), temporal resolution (for
imaging the beating heart), contrast (i.e. “soft tissue” reso-
lution), and sensitivity to a small number of cells or at a
minimum a therapeutic dose. Further, it should be com-
monly used clinically, require minimal operator depend-
ence, be inexpensive, and elicit minimal or no patient
discomfort. Importantly, no single imaging technique for
tracking stem cells has all the ideal characteristics. How-
ever, multimodality approaches can sometimes exploit the
advantages of each modality while moderating their re-
spective disadvantages.
When choosing a cellular labeling strategy, one should
reflect on the characteristics of the perfect cellular label.
Table 1 Clinical trials utilizing stem cells for the treatment of cardiovascular disorders
Trial Condition Cell types Delivery Route Select Functional Results
Strauer et al. [17] AMI BMC Intracoronary Increase in stroke volume index and ejection fraction. Significant decrease in ESV. Significant increase in the ratio of
systolic pressure to end-systolic volume.
Kuethe et al. [18] AMI BMC Intracoronary No improvement of LVEF, regional wall motion at infarcted zone, contractility index, coronary blood flow reserve or
maximal oxygen uptake at 3-months. No change in LV EF at 12 months.
BOOST [7,19-21] AMI BMC Intracoronary Overall treatment effect of BMC transfer on E/A. Significantly lower E/A ratio at 6 and 18 months for control group.
No difference in E/A ratio at 60 months between groups. No overall effect of BMC implantation on E(a)/A(a) ratio,
DT, IVRT, and E/E(a) ratio.
REPAIR-AMI [4,5] AMI BMC or CPCs Intracoronary No significant difference in LV volumes between groups, although a trend toward smaller ESVs in the BMC group;
significantly improved relative infarct size and regional contractility among BMC recipients.
ASTAMI [8,22] STEMI BMC Intracoronary No significant differences between groups in change of global LV systolic function at 3 years. Larger improvement in
exercise time from 2–3 weeks to 3 years in BMC recipients, but no difference in peak oxygen consumption.
REGENT [23] AMI Selected
(CD34 + CXCR+)
BMC, unselected BMC
Intracoronary Increased LV EF at 6 months in unselected and selected BMC recipients, but unchanged for control group. No
significant differences in absolute changes of LV EF between groups. No significant differences in absolute changes
of LV ESV and LV EDV for all groups.
TECAM [24] STEMI BMC Intracoronary At 9 months, no significant changes in changes in minimum lumen diameter and the percentage of stenosis at
follow-up between BMC and control group; no significant changes in the contralateral artery; and no changes in
maximum area stenosis and plaque volume.
Hopp et al. (subgroup
of ASTAMI) [25]
STEMI BMC Intracoronary For controls, improved global and regional LV function at 6 months versus 2–3 weeks; significantly more than in the
BMC group. Significant decrease in LV infarct mass; significantly more pronounced than the BMC group.
SWISS-AMI [26] AMI BMC Intracoronary Intracoronary BMMC did not improve LV function by CMR at 4 months relative to controls whether infused at
5–7 days or 3–4 weeks. Early reperfusion (<4.5 h) after STEMI predictive of more benefit from BMMC.
TIME [27,28] AMI BMC Intracoronary STEMI patients treated with PCI treated with intracoronary administration of autologous BMCs did not show
improved left ventricular function at 6 months or 1 year whether treated at 3 or 7 days after PCI.
LateTIME [6] AMI BMC Intracoronary Delayed (2–3 weeks) intracoronary injection of BMCs does not improve LVEF or regional wall motion or decrease
infarct size based on CMR compared to placebo-treated patients.
Fernandez-Aviles
et al. [29]
CMI BMC Intracoronary At 6 months among BMC recipients there was decreased ESV, improvement of regional and global LV function, and
increased thickness of the infarcted wall. No changes in control group.
IACT [30] CMI BMC Intracoronary At 3 months post BMC administration: decreased myocardial infarct size; improved global and regional LV function;
improved maximum oxygen uptake; and improved regional myocardial metabolism relative to non-treated controls.
Brehm et al. [31] CMI BMC Intracoronary Reduced infarct size, increased global LV EF and infarction wall-movement velocity for BMC recipients; no significant
changes for control group. Improved maximum oxygen uptake increased regional (18)F-FDG uptake into infarcted
tissue.
Janssens et al. [32] CMI BMC Intracoronary Increased mean global LVEF at 4 months in controls and BMC recipients; Decreased myocardial infarct size and
better recovery of regional systolic function in BMC group; Increased myocardial perfusion and metabolism in
controls and BMC patients.
Galinanes et al. [33] CMI BMC Intramyocardial Unmanipulated BMCs improved global and regional LV function at 6 weeks and 10 months for BMC that received
CABG.
Fuchs et al. [34,35] CMI BMC Transendocardial Among BMC recipients, stable ED LV volume; significant improvementof ESV and EF; improved regional contractility.
No significant improvements among controls.
Perin et al. [36,37] CMI BMC Transendocardial Improved LV EF from baseline and reduction in EDV in treated patients at 4 months. Significant mechanical

















Table 1 Clinical trials utilizing stem cells for the treatment of cardiovascular disorders (Continued)
PROTECT-CAD [10,11] CMI BMC Transendocardial After 6 months, significant increase in exercise treadmill time and LV F in BMC recipients. Significant decrease in
percentage area of peri-infarct regions; increase in global LVEF, percentage of regional wall thickening, and MPR over
target area at 6-months.
TABMMI [38] CMI BMC Transendocardial Transmyocardial delivery is safe with trends toward improved cardiac function in a non-randomized pilot trial.
vanRamshorst
et al. [39]
CMI BMC Transendocardial Significant increase in LV EF for BMC recipients. Filling pressure estimate E/E’ ratio improved at 3 months in BMC
group; no improvement in placebo group; significantly larger improvement in E/E(a) ratio for BMC recipients.
Significant increase in E/A peak flow ratio in BMC group.
Focus-CCTRN [40] CMI BMC Transendocardial No improvement in cardiac function with autologous BMMC delivered transendocardially.
Silva et al. [41] Heart failure BMC Transendocardial Improved mVO2 and METs for treated patients at 2 and 6 months. No significant difference in ESV, EDV, and LV EF
from baseline to 2 or 6 months.
Focus-HF [42] Heart Failure BMC Transendocardial Younger patients had improved cell function with improved responses compared to older patients.
TOPCARE-AMI
[5,43-45]
AMI CPC/BMC Intracoronary Persistent improvement of LV EF, significantly decreased LV ESV, and stable LV EDV through 5-year follow up.
Significant reduction in functional infarct size.
TOPCARE-CHD [46] CMI CPC/BMC Intracoronary Cross-over study from TOP-CARE AMI. Significantly greater LV EF among BMC vs. CPC recipients and controls.
Significant increase in global and regional LV function for BMC recipients, irrespective of cross-over status.
Bartunek et al. [47] AMI CD133 + BMC Intracoronary Significantincrease in LV EF and regional chordae shortening; associated increase in contractilityand decrease in
resting MIBI perfusion defect.
COMPARE-AMI [48] AMI CD133+ BMC Intracoronary LVEF improved at 4 months and 1 year compared to placebo treatment.
Goussetis et al. [49] CMI CD133 + BMC/
CD133-CD34 + BMC
Intracoronary Uptake of cells in the chronic ischemic myocardium.
Stamm et al. [50,51] AMI CD133+ BMC Transendocardial Enhanced global LV function and improved infarct tissue perfusion in 66% and 83% of BMC recipients, respectively.
Stamm et al. [52] Chronic
Ischemic HD
CD133+ BMC Intramyocardial Among CABG and cell therapy (vs. CABG alone) recipients, increased LVEF over baseline at discharge, 6, and
18 months and greater improvement in perfusion at the infarction zone.
Losordo et al. [53] CMI CD34+,G-CSF
mobilized PBC
Transendocardial Improved exercise time at 3 months in placebo and active treatment groups; slightly greater magnitude of




CD34+ cells Transendocardial Decreased frequency of angina and improved exercise tolerance
Choi et al. [55] AMI G-CSF mobilized PBC Intracoronary Significantly improved LVEF for cell therapy recipients after 6 months.
MAGIC Cell-DES [56] AMI/CMI G-CSF mobilized PBC Intracoronary Significant improvement in LVEF and ESV in cell recipients. In CMI patients, no significant change in LVEF and
ventricular remodeling; although, significant improvement of coronary flow reserve.
Chachques et al. [57] MI Skeletal myoblast Intramyocardial serum incubation during cell culture reduces immunological rejection of myoblasts. Significantly improved LV EF and
regional wall motion score index in cell-treated segments.
Dib et al. [58,59] MI Skeletal myoblast Intramyocardial For CABG patients receiving cell transplants there was significant improvement in mean LV EF; increased tissue
viability; and reduced ventricular systolic and diastolic volumes.
Herreros et al. [60] MI Skeletal myoblast Intramyocardial In the myoblast group, LVEF, regional contractility (in cardiac segments), global and regional viability and perfusion
improved significantly by 12 months.
Gavira et. al. [61]

















Table 1 Clinical trials utilizing stem cells for the treatment of cardiovascular disorders (Continued)
Hagège et al. [63] Heart failure Skeletal myoblast Intramyocardial Increased LV EF at 1-month and remained stable thereafter (median follow up of 52 months) for myoblast recipients.
ACD implantation can reduce arrhythmia risk.
Siminiak et al. [64] AMI Skeletal myoblast Intramyocardial Significantly increased L EF at 4 months; maintained through 12 month follow up.
POZNAN [65] Heart failure Skeletal myoblast Transcoronary
venous
Increased ejection fraction (3-8%) in two-thirds of cases.
Smits et al. [66] MI/Heart
failure
Skeletal myoblast Transendocardial Significantly increased LVEF at 3 months, but not at 6 months. At 3 months, significantly increased wall thickening at
target areas and less wall thickening in remote areas.
MAGIC [67,68] CMI Skeletal myoblast Intramyocardial No significant improvement of regional or global LV function for cell groups; significant decrease in LV volumes in
high-dose cell group vs. placebo group.
Veltman et al. [69] CMI Skeletal myoblast Intramyocardial No sustained improvement in 14 patients compared to matched controls at 4 year follow-up.
Chen et al. [70,71] AMI MSC Intracoronary Regional wall movement velocity increased significantly in the MSC group, but not controls. Significantly increased
LVEF at 3 months in MSC group compared with baseline and control group. Significantly improved perfusion defect
in BMSC group at 3 months compared with control group with synchronous decrease in LV EDV and ESV.
Significantly increased ESP: ESV.
Chen et al. [72] CMI MSC Intracoronary For MSC recipients, significant decrease in defect at 12 months; significantly improved level of exercise tolerance and
LVEF at 3 months.
Hare et al. [73] AMI Allogeneic MSC Intravenous Increased LVEF in MSC recipients in CMR subset.
MSC-HF [74] Heart Failure MSC Transendocardial Currently enrolling.
POSEIDON [75] CMI Autologous or
Allogeneic MSC
Transendocardial Allogeneic administration of MSCs is safe and has similar improvements as autologous.
TAC-HFT [76,77] CMI MSC or BMC Transendocardial Safety of transendocardial delivery of MSCs and BMCs in patients with CMI was found to be safe.
MyStromalCell
Trial [78]
CMI ASC Transendocardial Currently enrolling using adipose-derived stem cells primed with VEGF-A towards an endothelial progenitor lineage.
Frils et al. [79] Refractory
Angina
MSC Transendocardial Improved LVEF and systolic wall thickening in CMR subset.
Katritsis et al. [80] AMI EPC/MSC Intracoronary Significantly lower wall motion score index at 4 months in MSC group; Improved myocardial contractility in≥ 1
previously nonviable myocardial segment and restored uptake of 99mTc in≥ 1 previously nonviable myocardial scars
for BMSC recipients.
Lasala et al. [81] CAD EPC/MSC Intracoronary Significant improvements in LV EF and significant decrease in myocardial ischemia at 1 and 6 months.
Abbreviations: AMI acute myocardial infarction, BMC bone marrow cell, E peak early transmitral velocity, A peak late transmitral velocity, E(a) early diastolic velocity, A(a) late diastolic velocity, DT E-wave deceleration
time, IVRT isovolumic relaxation time, BM bone marrow, LV left ventricular, ESV end-systolic volume, EF ejection fraction, EDV end-diastolic volume, CAD coronary arterial disease, CMI chronic myocardial infarction,
F fluorine, FDG fluordeoxyglucose, MI myocardial infarction, BMMC mononuclear bone marrow cell, STEMI ST-elevation myocardial infarction, mVO2 myocardial volume oxygen consumption, MPR myocardial perfusion
reserve, METs metabolic equivalents, CPC circulating blood derived progenitor cells, HD heart disease, CD133+/CD34+ bone marrow-derived CD133+ or CD34+ cells, G-CSF granulocyte colony stimulating factor,

















Figure 2 Treatment effect of bone marrow cells (BM) implantation on percentage of total infarct area and peri-infarct area in the BM
group as determined by CMR. Data presented as mean ± SD (error bar). Reprinted with permission from Chan et al. [11].
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toxic, 2) requires no genetic modification of stem cells,
3) involves minimal or no dilution of the label with cell
division, 4) involves minimal or no transfer of the label
to non-transplanted cells, 5) possesses long-term stabil-
ity over months to years in vivo, 6) is quantifiable and
proportional to the cell number, 7) does not necessitate
injection of a contrast agent, 8) does not interfere with
normal cell function, and 9) is inexpensive [82]. It might
also be advantageous to have cell labeling schemes that
identify cells that have differentiated down a specific
lineage or can destroy cells that have differentiated down
an unwanted pathway.
Generally, cellular labeling techniques are classified as
receptor-based techniques, reporter gene labeling, or
direct labeling techniques. As the stem cell undergoes
differentiation, specific cell surface markers evolve
thereby limiting the relevance of receptor-based labeling
techniques in stem cell therapy. Further, reporter gene
labeling inherently alters the stem cell’s genetic material,
bringing about safety concerns likely to lengthen the
time to clinical acceptance. Currently, direct labeling
techniques serve as the primary means of labeling stem
cells for in vivo cardiovascular applications. With direct
labeling, the cellular marker (e.g. fluorescence probes,
MR contrast agents, and radionuclides) is taken up into
the cell or attaches to its surface; often direct cell label-
ing is performed in vitro prior to transplantation.
Many recent reviews describing tracking strategies for
studying stem cell based cardiac therapies are available
in the literature [83-97]. In this first of a two part review,
we will summarize the approaches, advantages, and dis-
advantages of stem cell tracking strategies for cardiovas-
cular applications and specifically highlight recent
developments in this rapidly developing field (Table 1)
with a particular emphasis on ultrasound and magnetic
resonance imaging technology. In part two of this re-
view, we will concentrate on optical and radionuclide
imaging technologies and discuss the growing use of mul-
timodality imaging techniques as well as our impressionsregarding the future of stem cell imaging in cardiac
therapy.
Noninvasive imaging modalities for stem cell tracking
The noninvasive imaging modalities employed in stem
cell tracking for cardiovascular applications in vivo in-
clude ultrasound, CMR, CT/X-ray fluoroscopy, radio-
nuclide imaging, and optical imaging. As mentioned,
each modality possesses its own set of advantages and
disadvantages, irrespective of the cell labeling strategy
employed. While anatomical localization using these im-
aging techniques is based on the ability to differentiate
between tissue types, the intrinsic contrast of stem cells
relative to native heart tissue is very low. Thus, stem
cells must be labeled either before or after transplant-
ation to detect them relative to the surrounding tissue.
Methodologies to label stem cells are described in
greater detail below by imaging modality, along with
unique advantages and disadvantages to each labeling
method.
CT/X-ray fluoroscopy, CMR, and US all depend on
physical properties which impart image contrast. In each
of these modalities, the final image is composed of signal
intensities that are transformed into gray scale images
corresponding to tissues possessing different physical
properties. In CT/fluoroscopy, CMR, and US the mea-
sured physical properties are electron density, nuclear
dipole relaxation time, and acoustic reflection (echogeni-
city), respectively. CT provides the highest spatial reso-
lution while CMR provides the greatest soft tissue
contrast. X-ray fluoroscopy and US provide higher tem-
poral resolution relative to CMR. Using a multimodality
imaging approach, such as highly interactive fluoroscopy
in combination with one having greater anatomic detail
(e.g., CTor CMR), may improve the accuracy of stem
cell placement as well as provide confirmation of initial
post-procedural targeting.
Unlike tissue-contrast based imaging, photon emission-
based imaging modalities (e.g., PET, SPECT and OI) gen-
erate images by detecting the release of light or other
Table 2 Stem cell tracking strategies for cardiovascular applications in vivo






• Iron oxides • High spatial resolution • Low sensitivity
• Gad-chelates • Signal not linked to cell
viability




• Lack of CMR-compatible
devices for interactivity
• No ionizing radiation
• Post-processing capabilities
• Not compatible for







• Gold Nanoparticles • High sensitivity • Ionizing radiation








• Liposomes • High potential of real-time
interactivity
• Difficultly with thin/
obese patients
• Microbubbles
• Microcapsules • Highly operator
dependent
• Perfluorocarbons • No ionizing radiation
• Interpretation has high
learning curve• Inexpensive
• Highly portable • Limited resolution











• High sensitivity • Poor anatomic detail
• High translational capacity • Poor interactivity
• Radionuclides,
e.g. 18 F-FHBG, 124I FIAU,
and 18 F-FDG
• Ionizing radiation
• Temporal limitations (due
to radioactive decay)
SPECT
• Radionuclides, e.g. 111In
oxine, 99mTc and18 F FDG














• Lacks clinical relevance• Low background




• High sensitivity • Photon attenuation
w/cell division
• Multiplexing
• Near-infrared probes • No ionizing radiation • Autofluorescence yields
high background
• Quantum dots • Low cost
• Small depth of
high-resolution• Permits short-term tracking
• Biohazardous labels
BLI: Bioluminescence imaging; 18F FDG: Fluoro-2-deoxy-d-glucose; FHBG: Fluoro-3-hydroxymethylbutyl; GFP: green fluorescent protein; 111In: Indium; PET: Positron
emission tomography; SPECT: Single photoelectron computed tomography; 99mTc: Technetium; US: Ultrasound.
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undergoes decay and emits a positron that travels in tissue
subsequently encountering an electron. Each positron-
electron “coincident” event results in an annihilation pair
that emits two gamma ray photons in the oppositedirection. Image acquisition is based on the external de-
tection of the emitted gamma pairs. SPECT is similar to
PET in its usage of a radioactive tracer and image acquisi-
tion based on detection of gamma rays. However, the radio-
tracer used in SPECT emits gamma radiation that is
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structed into a tomographic image, without a “coincident”
event. This difference accounts for the higher sensitivity ob-
tained from PET versus SPECT scans.
The OI modalities of bioluminescence and fluorescence
are photon emission-based as well; whereby electrons in
an excited state emit a photon upon returning to the
ground state with light subsequently being emitted in a
defined wavelength. The fundamental difference between
bioluminescence and fluorescence is the mechanism by
which the excited state is generated. Bioluminescent
photoproteins, such as luceferins, emit light as a bypro-
duct of a chemical reaction. Fluorescent compounds, also
called fluorophores (e.g., green fluorescent protein or GFP
or quantum dots), undergo excitation by incident light
and typically emit light at a different wavelength that can
be detected.
Because photon emission-based imaging techniques do
not measure tissue contrast, anatomic localization can be
difficult. Moreover, attenuation of photons by the tissue
can further complicate imaging in deep structures. For
these reasons, photon emission-based images are usually
acquired and interpreted in conjunction with tissue-
contrast based images; whereby the lack of tissue contrast
and relatively low spatial resolution of photon imaging
techniques is balanced by the exquisitely high sensitivity
of the anatomical imaging technique, such as CT.
In the clinical setting, PET-CT and SPECT-CT are
commonly used, and PET-MR is currently being rapidly
developed for clinical applications [98]. In general, pho-
ton emission-based imaging techniques have higher
sensitivity because of the introduction of non-native
substances that are measured. Thus, there is typically
no background signal that must be overcome for de-
tection with the exception of tissue autofluorescence
for optical imaging techniques. Photon emitting radio-
tracers are also very useful in imaging of metabolic pro-
cesses. Using radioisotopes to label biologically important
analogues and observe their behavior in vivo is useful
both clinically and experimentally. For example, con-
sider the lipophilic nuclear cardiac stress-test radiophar-
maceutical Technetium (99mTc) sestamibi. Technetium
(99mTc) sestamibi is distributed proportionally to myocar-
dial blood flow and freely crosses mitochondrial mem-
branes where it is accumulated, allowing a “snapshot” of
cardiac perfusion to be obtained at rest and during cardiac
stress [99]. Hence, multimodality imaging can be used to
exploit advantages while mitigating the disadvantages in
an individual imaging modality.
Stem cell labeling approaches by imaging modality
Ultrasound
Among the noninvasive imaging modalities, US continues
to be the most commonly utilized for cardiac structure andfunction evaluations, in part due to its non-invasiveness,
low cost, and portability. Moreover, the real-time interactiv-
ity of US and lack of ionizing radiation support the expan-
sion of this imaging modality for stem cell delivery and
tracking. However, until recently, ultrasound has been
scarcely utilized in stem cell tracking because of the diffi-
culty of attaching a long-lived ultrasound-visible label.
Tracking of stem cells via ultrasound can be done in
combination with microbubble contrast agents, acoustic-
ally active liposomes, or perfluorocarbon nanoparticles.
As previously stated, receptor labeling of stem cells is
problematic because stem cells often lose markers as
they differentiate as well as the inability to target ex-
ogenously delivered stem cells from native cells. One ap-
proach to overcome this problem has been spearheaded
by Leong-Poi and co-workers, who have genetically modi-
fied endothelial progenitor cells (EPCs) to express the
mouse H-2Kk protein [100]. Matrigel plugs containing H-
2Kk-expressing EPCs were implanted subcutaneously in
rats and subsequent ultrasound imaging demonstrated
in vivo targeting of lipid microbubbles with anti-H-2Kk
antibodies to the matrigel plugs whereas non-targeted
microbubbles were not visible ultrasonically [100]. Beyond
the disadvantage of genetic modification of stem cells, this
promising approach also will suffer from problems of de-
livery of the microbubble to stem cells that are far from
the vascular lumen. Because of this, most stem cell label-
ing using ultrasound has been targeted at adherence of
stem cells to the vascular lumen or atherosclerotic plaque.
In a recent in vitro study, bifunctional, fluorescent and
echogenic immunoliposomes (BF-ELIP) conjugated to
anti-ICAM-1 antibodies for targeting to the atheroma
were attached to bone marrow-derived CD34+ cells via
anti-CD34 antibodies [101]. These BF-ELIP- labeled
CD34+ bone marrow-derived stem cells were then incu-
bated with freshly harvested porcine aortic tissue; ultra-
sound was then employed to enhance adhesion of the
labeled cells to endothelium and enhance cell migration
through the vessel wall rather than imaging [101].
In a similar vein, Toma et al. coated MSCs with cat-
ionic, gas-filled lipid microbubbles (mb-MSC), and used
acoustic radiation generated by intravascular ultrasound
at 1.7 MHz to encourage mb-MSCs delivered intra-
aortically to adhere to the balloon-injured aorta in rabbits
[102]. At 24 hours post-delivery, engrafted mb-MSCs
remained localized to the luminal surface of the artery,
but showed little migration beyond their original location
on the luminal surface [102]. Recent refinements in this
technique [103] are aimed at enhanced targeting of stem
cells to specific sites of endothelial injury and additional
mechanisms to encourage engraftment beyond the vessel
itself.
Another approach is to use gold nanoparticles as acous-
tic reflectors. Nam et al. immobilized gold-labeled MSCs
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tracking [104]. Recently, internalization of polymer micro-
bubbles by bone marrow-derived mesenchymal stem cells
has been performed followed by in vitro ultrasound im-
aging [105]. The microbubbles, once internalized, remain
acoustically active, and emit harmonics that are not exhib-
ited by non-labeled stem cells. Unlike direct labeling with
gold, if the cell died, one would anticipate that the micro-
bubble shell integrity to degrade at which point detection
of microbubble by ultrasound would cease as well.
Despite these advances, ultrasound tracking of stem
cells is not widely employed as several significant hur-
dles must be overcome including: 1) the poor spatial
resolution inherent with ultrasound imaging: 2) the in-
trinsic echogenicity of contrast agents preventing accur-
ate cell quantification (agents cast acoustic shadows
beneath the first unit of contrast encountered); 3) con-
trast agents can be diluted with each subsequent cell
division; 4) agent stability is poor and higher stability
may lead to uptake by phagocytic cells once cells die; 5)
complicated acoustics result from uptake of the contrast
agent into the cellular space; and 6) a limited field of
view with the transthoracic, 2-dimensional-based tech-
nique thereby restricting access to many cardiac struc-
tures [82,106]. In 2012 using lessons learned from high
intensity focused ultrasound and enhance gene therapy
transfection with ultrasound, Ziadloo et al. used pulsed
focused ultrasound (pFUS) in a non-destructive manner
to enhance bone marrow stromal stem cell homing and
retention after intravenous administration to tissue treated
with pFUS [107]. Thus, ultrasound may be used in a var-
iety of ways to enhance cellular therapeutic engraftment
and to assess cardiac function after delivery even if not
directly used to track cells.
CMR
Cardiovascular magnetic resonance (CMR) typically in-
terrogates the distribution of water within a subject. The
high spatial resolution of CMR, as well as its capabilities
for generating images with three-dimensional (3D) ana-
tomical detail and lack of ionizing radiation makes CMR
attractive for clinical application.
Superparamagnetic- and paramagnetic-based cell tracking
CMR-based cellular tracking has been performed using
paramagnetic and superparamagnetic contrast agents as
well as non-proton-based contrast techniques. Detection of
labeled cells is related to magnetic field strength, labeling
efficiency, cell numbers, relaxivity and spatial resolution
[83]. Paramagnetic agents, such as gadolinium chelates and
dysprosium, act locally on nearby protons to cause them to
relax faster thereby shortening T1 relaxation. Gadolinium-
based contrast agents, which are approved for intravascular
administration, are used extensively in combination withT1-weighted imaging to increase signal in the vessels for
magnetic resonance angiography, dynamic perfusion assess-
ment in the heart, and viability assessment in the heart in
delayed contrast-enhanced imaging. However, for direct
stem cell labeling, paramagnetic agents have poor sensitiv-
ity due to the decreased effect on extracellular water once
the contrast agent is intracytoplasmic [108].
Iron oxide contrast agents are commonly categorized
based on particle size as: 1) superparamagnetic iron oxide
(SPIO), typically between 30–150 nm in diameter; 2) ul-
trasmall superparamagnetic iron oxide (USPIO), typic-
ally <30 nm in diameter; and 3) micron sized particles of
iron oxide (MPIOs) typically >1000 nm in diameter.
Superparamagnetic contrast agents create substantial dis-
turbances in the local magnetic field, which leads to a
rapid dephasing of protons. Gradient echo techniques that
cannot compensate for these dephasing artifacts will show
hypointensities in the vicinity of iron oxide particles ir-
respective of whether the nanoparticles are internal-
ized into the cell or not [83]. Thus, the sensitivity for
tracking cells labeled with iron oxide nanoparticles is
much higher than paramagnetic agents. To maximize
the sensitivity to the magnetic susceptibility effects of
USPIO/SPIO/MPIOs, T2*-weighted sequences are typ-
ically used. However, image interpretation may become
difficult due to other endogenous sources of magnetic sus-
ceptibility, including hemorrhage and tissue interfaces,
which also can create hypointensities on T2*-weighted im-
ages. Nonetheless, SPIOs have been used in a number of
non-cardiac clinical trials for cell tracking outside the
United States [109-114].
Many preclinical studies have now been performed
using iron oxide nanoparticles to help assess the optimal
timing, stem cell type, dose, etc. In 2003, two studies
heralded the use of iron oxide-labeled stem cells for car-
diovascular cell delivery and tracking in large animals
with CMR [115,116]. The first study by Kraitchman
et al. [115] used a technique called “magnetofection” to
label stem cells with ferumoxides, a clinically approved
SPIO for liver imaging. In this study, the uptake of the fer-
umoxides in non-phagocytic, bone marrow-derived MSCs
was enhanced by the addition of a transfection agent, poly-
L-lysine. The concept of combining SPIOs with transfec-
tion agents to enable rapid cell labeling without species or
cell specificity developed by Frank and Bulte [117]. In this
first study, CMR tracking of the SPIO-labeled MSCs after
transmyocardial injection was performed in a swine, reper-
fused myocardial infarction model (Figure 3). In this study,
~30% of the injections of SPIO-labeled stem cells injected
under X-ray fluoroscopic guidance were not visible under
CMR indicating that perceived successful injections did
not occur. Extrapolating these results to clinical trials with
non-labeled cells, one could anticipate that there may be a
variable response in clinical trials due to intermittent
Figure 3 Long-axis CMR showing hypointense lesions (arrows)
caused by superparamagnetic iron oxide-labeled mesenchymal
stem cells acquired within (top left) 24 h and (bottom left)
1 week of injection. Insets demonstrate expansion of lesion over
1 week. Reprinted with permission from Kraitchman et al. [115].
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beling, it is impossible to assess whether the therapeutic
failed because of failure of the stem cells to be delivered,
failure of the therapeutic to be retained in the heart or fail-
ure of the therapy itself due to a poor choice of injection
dose, cell type, or timing of injection.
Hill et al. quickly followed with a similar study in
swine using MPIO-labeled MSCs which were tracked up
to three weeks after injection [116]. Building on this
study, Dick et al. targeted MPIO-labeled MSCs to the
infarct borders using a specialized active MR injection
catheter and MR fluoroscopic imaging [118]. The advan-
tage of the latter technique is that the success of the cell
delivery could be immediately determined. Furthermore,
using viability assessment with late gadolinium enhanced
CMR [119], the cellular therapeutic could be specifically
targeted to the peri-infarcted and infarcted tissue. In par-
ticular, Bulte and Kraitchman showed migration of stem
cells in a reperfused dog infarction model over 8 weeks in
the peri-infarction region [84]. SPIO-labeled MSCs were
consistently removed when injected into normal myocar-
dium whereas persistence of SPIO-labeled MSCs was
noted in infarcted myocardium (Figure 4) [120].Electromechanical mapping is another technique to
target iron-labeled cellular therapy to viable myocardium
and was first shown by Garot and colleagues for stem
cell delivery in swine with infarcted myocardium [121].
In this study, injections in both normal and infarcted
myocardium were all confirmed on CMR [121]. These
results are in contrast to Kustermann and co-workers,
who had difficulty differentiating the hypointensities cre-
ated by USPIO-labeled cardiac progenitor cells from
hypointensities due to the cryoablation or territory served
by permanent coronary artery ligation to create damaged
myocardium in mice. Presumably some of these issues
were a result of the infarction model, small animal size,
and small iron oxide particle size.
A variety of other investigators have studied iron
oxide-labeled stem and progenitor cells with CMR
[122-127]. In a novel approach, Weber et al. [122] used
magnetic beads designed for cell sorting to select endo-
thelial progenitor cells, i.e., CD34 magnetic beads. How-
ever, the long-term retention of these magnetic beads on
cells in vivo has never been fully investigated. In another
murine study, Tallheden et al. injected SPIO-labeled em-
bryonic stem cells under direct visualization in the anterior
left ventricle and demonstrated hypointensities consistent
with the labeled cells [123]. Subsequently, two additional
groups demonstrated long-term tracking of SPIO-
labeled stem cells in infarcted hearts [124,125]. Stuckey
et al. were able to track SPIO-labeled bone marrow-derived
stromal cells up to 16 weeks post-infarction with CMR
[124]. Ebert et al. not only tracked SPIO-labeled cardiac-
differentiated mouse embryonic stem cells up to 28 days
post-administration in a reperfused myocardial infarction,
but also showed using CMR that declines in cardiac
function were moderated by reductions in adverse remod-
eling [125]. Using MPIO-labeled amniotic fluid stem
cells, Delo et al. were also able to demonstrate per-
sistence of these cells up to 4 weeks after administration
using CMR that was confirmed histologically [126]. Simi-
larly, Chapon et al. [127] were able to demonstrate using
CMR the persistence of hypointensities from rat bone
marrow-derived stem cells labeled with a tat-peptide-
USPIO nanoparticle [128] injected intramyocardially in
both infarcted and sham operated rats at 6 weeks post-
administration. A fluorescent label, FITC, in the tat-UPIO
nanoparticle was used for histological validation. Despite
using a 9.4 T CMR system, tracking of the hypointensities
was more problematic, which the authors attributed to the
smaller iron oxide nanoparticle used in this study.
Tracking of bone marrow-derived MSCs has been
shown in a swine, reperfused infarction model by Hare
and co-workers [129,130]. In the first study [129], the
appearance of increased subendocardial myocardium in
the infarct zone in close proximity to stem cell injections
was shown on multi-detector CT, and the presence of
Figure 4 Delayed contrast-enhanced (DCE) long-axis image (left) demonstrating infarcted myocardium (MI). MR-labeled-MSC injections
appear as hypointense areas on fast gradient echo images. Serial imaging at 72 hours, 1 week, 2 weeks, 4 weeks, and 8 weeks demonstrates the
persistent of the MR-MSC injections. The volume of injections decreases over time. In addition, an injection placed in the normal myocardium
(arrow) can no longer be detected at 4 weeks post-injection. Reprinted with permission from Soto et al. [120].
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[131,132]. In a subsequent study [130], first pass contrast-
enhanced CMR showed increased perfusion in the treated
animals relative to controls prior to any functional benefit
suggesting that MSCs may assist with angiogenesis and
reduce apoptosis [130].
While these studies confirmed the presence of hypoin-
tensities on CMR corresponded to the exogenously la-
beled cells using histopathology, a number of studies
have raised the concern that CMR hypointensities may
reflect loss of the iron oxide nanoparticle from dead cells
that either remains in the interstitial space or iron oxide
nanoparticles that are taken up by phagocytic cells. In
particular, Terrovitis et al. performed SPIO labeling of
human and rat cardiac-derived stem cells (CDCs) that
expressed beta-galactosidase and injected them intra-
myocardially in normal rats [133]. Persistence of hypoin-
tensities occurred for three weeks by CMR yet no CDCs
were detected histologically. As expected, the area of
the hypointensities decreased to a greater extent in the
animals receiving xenogenic CDCs, presumably due to
immunorejection, relative to the syngeneic CDCs whereas
the hypointense area remained fairly constant from day 2
to day 21. Interestingly, the MR images in this study dem-
onstrated a greater reduction in the hypointense area in
the syngeneic animal compared to the xenogenic animal.
Schwaiger and colleagues performed a similar study in
immunocompromised rats that received intramyocardial
injections of iron oxide-labeled human endothelial pro-
genitor cells (hEPCs) that were transfected with a PET
reporter gene, the sodium iodide symporter (NIS) [134].
Both PET and CMR demonstrated the presence of the
hEPCs at 24 hours post-injection. Hypointensities on
CMR were still present at 72 hours and one week post-
injection. On the other hand, PET imaging failed to
detect any viable hEPCs at 1 week. Yet, immunohisto-
chemistry at one week was unable to detect any of the
exogenously hEPCs whereas staining for iron with Prus-
sian Blue demonstrated co-localization of the iron withCD68+ cells, i.e., macrophages. While the authors note
that PET imaging cannot detect less than 10,000 cells,
the postmortem histology would suggest two things: 1.
hEPCs did not survive even in an immune-compromised
animal and 2. iron released from dying hEPCs is retained
in macrophages that are still present at 1 week post-
injection. In a related study, Li et al. performed serial
imaging of SPIO-labeled human embryonic stem cells
(hESCs) expressing a bioluminescence reporter gene that
were injected into the hind limb of immunocomprom-
ised mice [135]. Undifferentiated ESCs are known for
rapid proliferation and teratoma formation in vivo. As
expected in this study, the development of teratoma re-
sulted in an increased bioluminescence signal yet the
CMR signal remained relatively constant. These reporter
gene/CMR studies highlight two potential problems with
direct labeling schemes: 1. that cell viability/proliferative
capacity cannot be assessed and 2. that the label itself
may become detached from the cell of interest. As such,
direct labeling methods with SPIOs are best suited for
targeting delivery and determining initial success rather
than tracking cell viability. For long-term tracking, one
must be cognizant that hypointensities may overestimate
viable cells if free SPIOs or phagocytic cells, which scav-
enge the free SPIO, persist in the tissue. This issue is a
problem in most cellular direct labeling methods.
Another issue with iron oxide nanoparticles is that the
hypointensities created by the labeled cells compromise
visualization of underlying tissue anatomy. Furthermore,
other substances, such as air-tissue interfaces and metallic
objects, e.g., stents, will create susceptibility artifacts that
may mimic the hypointensities seen on T2*-weighted im-
aging of iron oxide-labeled cells. In an effort to overcome
some of these issues, several techniques were developed
based on a gradient dephasing technique by Seppenwoolde
and co-workers [136] to passively track gadolinium-based
markers, which cause local field inhomogeneities, in inter-
ventional devices. Using a twist on Seppenwoolde’s
white marker technique and static dephasing theory of
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[137], Mani et al. developed a slice-selective gradient echo
technique for positive marker tracking of stem cells called
GRASP [138-140]. However, these dephasing techniques
are very sensitive to imaging parameters, such as slice
thickness and echo time. Alternative positive contrast
SPIO imaging techniques have been developed that em-
ploy spectrally selective excitation/suppression [141-143].
The spectrally-selective radiofrequency excitation and re-
focusing of off-resonant water frequencies proposed by
Cunningham and colleagues [141] has been used in vivo
to track embryonic stem cells implanted in the leg [135]
and is best suited for spin echo techniques, which may
limit applicability in the heart. An alternate off-resonant
technique called inversion recovery with on-resonant
water (IRON) saturates the water and fat peaks so that the
off-resonant protons in close proximity to the SPIO-
labeled stem cells are enhanced [142]. An added benefit to
IRON imaging is that it can be used with either gradient
echo or spin echo pulse sequences and can be applied
across vendor platforms without any special pulse pro-
gramming or post-processing of the images (Figure 5). Be-
cause these imaging techniques only preserve the
susceptibility artifacts from the iron oxide-labeled cells, an
additional anatomical reference image is needed. Alterna-
tively Dahnke et al. have developed a post-processing
method to determine the susceptibility gradient map from
conventional gradient echo images to create positive con-
trast images of SPIO-labeled cell [144]. Thus, the standard
anatomical image is obtained and no specialized pulse se-
quences are required. More recently, Garwood and co-
workers have employed sweep imaging with Fourier
transformation (SWIFT) for the detection of SPIO-
labeled stem cells in the rat heart [145]. Using SWIFT,
there is very little time between radiofrequency excitation
and signal acquisition, which makes it well suited forFigure 5 Left: An axial positive contrast image using Inversion-Recov
stem cells injected in a rabbit thigh demonstrates two injection sites
projection of a 3D T2-prepared MR angiogram shows the region of superfi
model of peripheral arterial disease can be registered with the IRON im
neovasculature. (Adapted with permission from Kraitchman and Bulte [imaging iron oxide labeling where the T2* relaxation time
is very short. Interestingly, the magnitude image from
SWIFT provides anatomical detail whereas the imagin-
ary component provides a positive contrast image. How-
ever, the implementation of SWIFT is not available on
commercial MR scanners nor is post-processing of the
SWIFT images available currently. Another approach that
has shown promise is to use ultrashort echo time (UTE)
techniques available on clinical systems to acquire the T1
signature of iron oxide-labeled cells to create a positive
contrast image [146,147].
At one time, when clinically approved SPIOs, i.e., ferum-
oxides and ferucarbotran, were available, translation of
SPIO-labeling clinical cardiovascular stem cell trials showed
promise because of ease of labeling and low toxicity of the
label if only to confirm stem cell delivery. However, these
SPIOs have ceased to be manufactured for economic rea-
sons [148]. Interest in USPIO labeling has been renewed
with several groups demonstrating an off-label use of an
FDA-approved injectable ferumoxytol for the treatment of
iron deficiency anemia in adults with chronic kidney dis-
ease (Feraheme, AMAG Pharmaceuticals) to label a variety
of cells [149,150].
Non-proton labeling methods
One potential solution to the problems associated with
direct cell labeling with iron oxide nanoparticles would
be to use a label that is rapidly removed if the cell dies,
similar to microbubbles, which are under development
for ultrasound cell labeling. In 2003, Ahrens et al. ex-
ogenously labeled dendritic cells with perfluorocarbons
and performed in vivo tracking after direct tissue or
intravenous injection in mice using Fluorine (19 F) MRI
[151]. Because there is very little native fluorine in the
body apart from the teeth, one can be exquisitely sensi-
tive to fluorine labeled cells with the creation of hot-ery with On-resonance water suppression (IRON) of SPIO-labeled
(arrows) as bright hyperintensities. Right: A maximum intensity
cial femoral artery occlusion at 24 hours post-occlusion in a rabbit
ages to determine the location of stem cell injections relative to
108]).
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2007, Partlow et al. labeled human umbilical cord pro-
genitor cells with two different perfluorocarbon nanoparti-
cles and demonstrated the ability to detect as few as 2000
labeled cells at 11.7 T in vivo and 1 million cells ex vivo
at 1.5 T [152]. These cells were labeled with the per-
fluorocarbons by simple incubation without a transfection
agent. Presumably, should the cells die, the perfluoro-
carbon would be excreted via the lungs rather than be-
ing retained in tissue. Subsequently, Barnett et al.
labeled pancreatic islet cells with these same two per-
fluorocarbons and performed the first in vivo studies
showing fluorine CMR in a clinical 3T scanner with
retention of the labeled cells in the renal capsule of
rabbits (Figure 6) [153]. While the scanner must have
multinuclear capabilities and transmit/receive coils to
detect the fluorine signal, this study demonstrates the
potential for translation to clinical studies. Further aiding
possible clinical translation is the availability of clinically
approved perfluorocarbon agents that are used for echo-
cardiography and as blood substitutes.
Another strategy that was originally designed to en-
hance survival of allogeneic cell therapies is microencap-
sulation. In the 1980s, alginate microencapsulation wasFigure 6 In vivo merged 19 F (color) and proton (grayscale) MRI
acquired on a clinical 3T scanner of a rabbit transplanted with
10,000 perfluoropolyether (PFPE)-labeled islets under the
kidney capsule demonstrates clear visualization of cell
transplants. The signal corresponds to 14,153 μg PFPE. Reprinted
with permission from Barnett et al. [153].developed by Lim and Sun [154] as a method to immu-
noisolate islet cells for transplantation in Type I diabetes
mellitus. Typically alginate microencapsulation is per-
formed in a multi-layer approach, e.g., alginate-poly-L-
lysine-alginate (APA), to enhance the porosity of the
capsule while retaining strength and biocompatibility.
Thus, the APA microencapsulation technique enhances
survival of allogeneic or xenogenic cells by restricting the
passage of large molecules, e.g. immunoglobulins, while
simultaneously allowing small molecules, e.g., oxygen, nu-
trients, cytokines, and waste products, to exchange across
the membrane. Initially, Barnett and coworkers recog-
nized that the poly-L-lysine moiety could be used for iron
oxide labeling of the microcapsule and exploited this con-
cept for tracking islet cell transplantation [155,156]. More
recently,this group has modified the formulation to in-
corporate perfluorocarbons for microcapsule tracking
using fluorine MRI [157,158]. One immediate advan-
tage of this technique is that higher concentrations of the
labeling agent can be added to the microcapsule without
affecting cell viability, thus enhancing sensitivity. Using
positive contrast techniques [142], this group has also
demonstrated that one may be able to monitor the integ-
rity of the iron oxide-labeled cell capsules [155]. Arifin
et al. have shown that gadolinium chelates may also be
incorporated into the alginate microcapsules when linked
to a gold nanoparticle, which are visualized as hyperin-
tense signals on T1-weighted MR images at 2-days after
delivery [159]. However, similar to direct labeling tech-
niques, this method of tracking cannot directly report the
viability of the cell.
Reporter gene imaging
MRI reporter gene-based labeling entails the transfection
of genetic material with plasmids or viral vectors to
induce the cell to produce a specific receptor, protein,
or enzyme that usually can be detected by the intro-
duction of a reporter probe. One of the advantages of
reporter gene imaging is that only live cells will pro-
duce the reporter gene product. Furthermore, if the
reporter gene is not constitutively expressed but ra-
ther only by a specific promoter, there is the potential
of imaging stem cell fate once differentiation down a
specific lineage has occurred.
One of the earliest examples of MR reporter genes en-
abled imaging of gene expression. The approach by
Louie et al. was to use a paramagnetic contrast agent
whose access to water was blocked until cleaved by an
enzyme [160]. Thus, cells expressing the enzyme would
create an active form of the paramagnetic contrast agent
and show increased intensity on T1-weighted images.
Another approach to MR reporter gene imaging tech-
niques was to transduce cells to overexpress a native pro-
tein, ferritin, which is responsible for iron storage within
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more iron within the cell leading to a signal amplification
that can be several folds greater than with direct receptor
binding to the cell. Campan et al. recently demonstrated
overexpression of the human ferritin heavy chain (hFTH)
as a MRI reporter gene for in vivo tracking of swine car-
diac progenitor cells in the infarcted rat heart [161].
Lentiviral-transduced cardiospheres (CSCs) overex-
pressing hFTH were injected intramyocardially at the
perimeter of the infarct [161]. Iron accumulation in
the rat hearts was followed up to 4 weeks using a multie-
cho, T2* gradient echo sequence on a 1.5 T clinical
scanner [161]. While there is some concern that in-
creased iron accumulation in the cell may be detrimen-
tal, CSC differentiation down multiple lineages still
occurred [161], which would suggest that stem cell
pluripotency was retained despite genetic manipula-
tion and iron uptake. An MR reporter gene approach
that does not rely on MR superparamagnetic or para-
magnetic compounds has been explored in the brain.
Gilad et al. used overexpression of lysine-rich residues
as an endogenous contrast agent with increased amide
residues, which could exchange protons with water resi-
dues [162]. Using chemical exchange saturation transfer
(CEST) imaging [163], transfected cells could be distin-
guished from non-transfected cells in the brain [162].
Because paired images with and without radiofre-
quency irradiation are required for CEST, cardiac mo-
tion may be extremely challenging for implementation
of this reporter gene approach.
One of the primary potential advantages of MR re-
porter gene imaging is that the reporter gene should be
passed to the daughter cells and, thus, issues associated
with label dilution during cell proliferation/division is
markedly reduced. On the other hand, one must make
sure that genetic expression as well as uptake of the re-
porter probe does not affect cell viability and function.
In addition, there are concerns about the long-term ex-
pression of the foreign genetic material. Fortunately, si-
lencing of the reporter gene often occurs over time,
which may reduce fears of delivering a genetically altered
cells to young cardiovascular disease patients.
CMR has several remaining hurdles to overcome as it
relates to stem cell therapy for cardiac applications. For
instance, quantification of labeled cell populations is
challenging with the direct labeling schemes as there is
dilution of intracellular markers with every cell division
and there is potential for accumulation of iron particles
within phagocytic cells that may lead to the produc-
tion of false signals. Further, there is low sensitivity
relative to radionuclide imaging, a lack of compatible
devices for real-time delivery using CMR, MR contra-
indications in many cardiac patients due to metallic
implants, the high expense of the CMR equipment, ahigh degree of acoustic noise, and relatively poor
physiological monitoring for the acute cardiac patient.
However, the lack of exposure to ionizing radiation to
the patient, operator, and stem cells themselves in
addition to the ability to determine myocardial viabil-
ity, function, and perfusion in a regional manner have
resulted in more frequent use of CMR to assess pa-
tients after stem cell delivery in cardiovascular clinical
trials [5-7,9,74,75,78,79,164,165].
X-ray
X-ray based imaging modalities include computed tom-
ography (CT) imaging and X-ray fluoroscopy. The high
spatial resolution and real-time interactivity are highly
desirable attributes of these X-ray-based imaging mo-
dalities for clinical assessment and treatment of the
heart. However, concerns about ionizing radiation dose
and the limited ability to directly visualize soft tissue, such
as the myocardium, are major drawbacks. Furthermore,
most X-ray contrast agents are not amenable for direct
cell labeling due to their high toxicity at relatively low
doses.
Recently, Ricel et al. have develop a gold nanoparticles
coated with poly-L-lysine for direct stem cell labeling
[166]. To enhance biocompatibility, gold nanoparticles
are typically coated with substances, such as poly-
ethylene glycol (PEG), which in turn inhibits direct
uptake of the nanoparticle by stem cells. Unlike MRI
labeling compounds, gold nanoparticles have been shown
to be actively expelled via exocytosis by cells [167].
Thus, loss of a gold label may occur even without cell
division.
The development of MR-labeled alginate microcap-
sules has also been translated to X-ray-visible micro-
capsules. As with MRI, this allows the use of high
concentrations of X-ray-visible contrast agents in the
microcapsules without cellular toxicity for tracking
using conventional X-ray fluoroscopic and computed
tomography (CT) [156,157,168,169]. Impregnation of
APA microencapsulation with barium or bismuth sul-
fate allowed in vivo tracking of microcapsules in mice
and rabbits using conventional X-ray fluoroscopy [156,168].
These bariumsulfate-labeled microcapsules were also used
to confirm delivery and retention of allogeneic MSCs in a
rabbit model of peripheral arterial disease (Figure 7)
[169-171]. Single microcapsules could be seen in vitro
using cone beam CT, although, in practice, several thou-
sand microcapsules would be expected as a minimum to
achieve a therapeutic effect. Another formulation using
perfluoroctylbromide (PFOB) enables capsule tracking
with X-ray, MRI, and ultrasound and may be useful for
allowing delivery using X-ray fluoroscopic or ultrasound
techniques while reducing radiation dose by using MR or
ultrasound imaging for follow-up (Figure 8) [157].
Figure 7 Barium sulfate-labeled microcapsules for X-ray cell tracking (Xcaps) in peripheral arterial disease. (A) A bar graph of the
average modified Thrombolysis In Myocardial Infarction (TIMI) frame count, as a measure of collateral vessel development, in the MSC-Xcaps,
empty microcapsules, unencapsulated MSCs, and sham injection treated animals demonstrating a significant improvement in distal filling only in
the peripheral arterial disease (PAD) rabbits that received microencapsulated cells (*P < 0.001 empty microcapsules vs. MSC-Xcaps; P = NS naked
MSCs vs. sham injections). B-G: Representative digital subtraction angiogram (DSA, red) obtained during peak contrast opacification performed
at two weeks post injection of encapsulated MSCs-Xcaps (B) and empty microcapsules (C) with an overlay of microcapsules injections (green)
obtained from mask image of DSA. The small collateral vessels are somewhat obscured by the Xcap radiopacity. However, the increased
collateralization can be appreciated in the MSC-Xcap-treated animal DSA (D) relative to the Xcap-treated animal (E) Native mask digital radiographs
demonstrating the location of the MSC-Xcaps (F) and empty Xcaps (G) in the same animals. There was no statistically significant difference in vessel
diameter between treatment groups. Reprinted with permission from Kedziorek et al. [171].
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niques in the heart is the large size of the microcapsules,
which is ~300-500 μm. Thus, this labeling method is
not amenable to intravascular or transmyocardial de-
livery due to concern about vascular occlusion or in-
duction of conduction abnormalities. As such, these
techniques may be better suited for treatment outside
the heart. Moreover, since the cells are trapped within
the microcapsule, direct incorporation into the myocar-
dium is unlikely. In 2011, Azene et al. demonstrated that
an alternate delivery site for X-ray-visible microcapsules
may be the pericardial space [173]. Using myocardial
borders derived from a navigator- and cardiac-gated
whole heart CMR at 1.5T fused with real-time X-ray
fluoroscopy, barium sulfate impregnated microcap-
sules were delivered to the pericardial space in swineon a clinical angiographic system (Figure 9) [173]. These
studies build upon X-ray fused with MRI (XFM) tech-
niques [174,175] developed in preclinical applications
[176] for ultimate translation to pediatric and adult car-
diac interventions [177,178].
Summary
In the past 10 years, there have been a large number of
preclinical studies and clinical trials that have used CMR
to delivery, track, or determine the efficacy of stem cell
therapy in the heart. While X-ray cell labeling techniques
are not as mature at present for translation to clinical tri-
als, the ability to fuse multiple image modalities, such as
radionuclide imaging, CT, or MRI, with X-ray fluoroscopic
imaging offers the ability to obtain the optimal interact
interface for cell delivery with anatomical, functional, and
Figure 8 Perfluorocarbon-labeled microcapsules for X-ray visible cell tracking by CT. (A) Cone beam CT acquired on a flat-panel X-ray
angiographic system (Axiom Artis, Siemens AG, Forchheim, Germany) demonstrating the detection of four perfluorooctylbromide (PFOB) injection
sites in a rabbit medial thigh, while unlabeled capsules in the left thigh are not detectable. (B) 19 F MRI of the same rabbit showing one-to-one
correspondence to the injection location on cone beam CT. (C) Co-registering of threshold cone beam CT image of a rabbit with 6 PFOB Caps
injection sites (gray) and postmortem 3D rendering volume of each injection sites (color) demonstrating the location of opacities on cone beam
CT image is representative of PFOB Caps injections. Registration error for each injection site from a representative rabbit is shown. Reprinted with
permission from Fu et al. [172].
Figure 9 X-ray fused with MRI (XFM) of X-ray-visible microcapsules to the heart. (A) Segmented cine CMR showing epicardial contours
(green-RV; blue-LV) overlaid on live X-ray fluoroscopic image. (B) Coronary vasculature from c-arm CT overlaid on live X-ray fluoroscopic image.
(C) Live X-ray fluoroscopy demonstrating radiopacity of needle used for pericardial puncture and the lack of ability to visualize the myocardium
or coronary vasculature without XFM. (D) Live X-ray fluoroscopy image overlaid on segmented whole heart CMR and c-arm CT volumes showing
pericardial puncture. (E) An M-mode echocardiogram at seven days post-injection demonstrating normal cardiac function and no abnormalities
to the pericardium. Reprinted with permission from Azene et al. [173].
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